Yili Chuanning Biotechnology Co.,Ltd.

301301

CNE100005WX0

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
13.3 ^CNY	+0.45%		-4.73%	+58.33%

May. 14	Yili Chuanning Biotechnology Co.,Ltd. Approves Cash Dividend for the Year 2023	CI
Apr. 21	Yili Chuanning Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Yili Chuanning Biotechnology Co.,Ltd.(SZSE:301301) added to Shenzhen Stock Exchange Component Index

December 12, 2023 at 12:00 am EST

Yili Chuanning Biotechnology Co.,LtdAdded to Shenzhen Stock Exchange Component Index.

Latest news about Yili Chuanning Biotechnology Co.,Ltd.

Yili Chuanning Biotechnology Co.,Ltd. Approves Cash Dividend for the Year 2023	May. 14	CI
Yili Chuanning Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 21	CI
Yili Chuanning Biotechnology Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Yili Chuanning Biotechnology Signs Cooperation Deal With Jinhui Technology	Feb. 23	MT
Certain A Shares of Yili Chuanning Biotechnology Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-DEC-2023.	Dec. 26	CI
Yili Chuanning Biotechnology Co.,Ltd.(SZSE:301301) added to Shenzhen Stock Exchange Component Index	Dec. 12	CI
Yili Chuanning Biotechnology Co.,Ltd.(SZSE:301301) added to Shenzhen Stock Exchange Component A Share Index	Dec. 12	CI
Yili Chuanning Biotechnology Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-23	CI
Yili Chuannig Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
Yili Chuannig Biotechnology Co., Ltd.(XSEC:301301) added to S&P Global BMI Index	23-06-19	CI
Yili Chuannig Biotechnology Co., Ltd. Implements Final Cash Dividend on A Shares for 2022, Payable on 29 May 2023	23-05-22	CI
Yili Chuannig Biotechnology Co., Ltd. Approves Directorate Appointments	23-05-08	CI
Yili Chuannig Biotechnology Co., Ltd. Approves Final Cash Dividend for 2022	23-05-08	CI
Yili Chuannig Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Yili Chuannig Biotechnology Co., Ltd. Proposes Final Cash Dividend for 2022	23-04-03	CI
Shanghai Ruikang Biotechnology R&D Co., Ltd. announced that it expects to receive CNY 100 million in funding from Yili Chuannig Biotechnology Co., Ltd.	23-03-30	CI
Yili Chuannig Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-12	CI
Yili Chuannig Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-12-06	CI

Chart Yili Chuanning Biotechnology Co.,Ltd.

Duration

Period

Chart Yili Chuanning Biotechnology Co.,Ltd.

More charts

Yili Chuanning Biotechnology Co Ltd is a China-based company mainly engaged in the research, development and industrialization of biological fermentation technology. The Company's products mainly include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, crude ursodeoxycholic acid, coenzyme Q10 mycelium and others. The Company's products are mainly exported to countries such as India.

Sector

Pharmaceuticals

Calendar

2024-08-19 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Yili Chuanning Biotechnology Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.3 CNY

Average target price

10.6 CNY

Spread / Average Target

-20.30%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
YILI CHUANNING BIOTECHNOLOGY CO.,LTD.	+58.33%	4.09B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals